Nasdaq GlobeNewswire

Medibio building credentials to "scale" via appointment of healthcare & telehealth icon to Board of Directors

Del

SYDNEY, Australia and MINNEAPOLIS, July 19, 2017 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a digital health company that has developed an objective testing system to assist in the screening, diagnosis and treatment effectiveness of depression, chronic stress and other mental health disorders, is pleased to announce the appointment of Dr Adam Darkins, MB, ChB., MPHM, M.D., FRCS to the Board of Directors as Deputy Chairman. Dr Darkins has unique experience in taking national and trans-national virtual care delivery systems to scale.

Medibio Board member and fellow physician, Dr Frank Prendergast, M.D. said, "Adam is a wonderful addition to the Medibio Board. He complements our team, drawing on a wealth of experience gained from the practice of medicine, health care management, and having built one of the world's largest, telehealth programs. His proven track-record in tackling one of the current greatest healthcare challenges - how to introduce transformational new technologies that demonstrably increase access to care and reduce its cost - is what makes him so unique. His creativity and rigour, in design, and continuing development, of innovative care systems will help guide Medibio to meet anticipated milestones in our growth trajectory as we transition from clinical validation to regulatory approval, and then commence broader implementations. Adam will help us to lay the strategic foundations for large-scale operations in the pre-eminent health care systems of the future."     

Dr Darkins developed an extensive understanding of patient care, clinical processes, and outcomes measurement from his physician training at Manchester University Medical School, UK, and further training/accreditation as a neurosurgeon and researcher at UCLA. Studying public health medicine at the London School of Hygiene and Tropical Medicine, and pioneering shared patient decision-making programs at the King's Fund, London, grounded him in leading transformative change with a particular talent for safely and effectively taking long-established hospital-based practice into primary care, community care and non-traditional settings. Thereafter, already renowned for his ability to utilise new information and telecommunication technologies to empower patients, increase access to care and reduce cost, he gained widespread US and international recognition for his leadership of telehealth programs at the US Department of Veterans Affairs (VA). At VA he developed health informatics, telehealth and disease management technologies to enhance and extend care and case management. Together with his team, Dr Darkins created a capacity that delivered virtual services to more than 480,000 Veteran patients each year via 1.4 million episodes of care. On any given day, 83,000 Veteran patients were using home-telehealth technologies to live independently at home and avoid institutional care.

Dr Darkins comes to Medibio from Medtronic Plc where, as Vice President for Innovation and Strategic Partnerships for the Americas Region, he worked on using new payment models to transform health care. He has been permanently based in the USA since 1997. Dr Darkins serves on the editorial board of Telehealth and e-Health Journal; is a former Medical Director in London; co-founded a start-up telehealth company; and has both written, and spoken widely on how to address the challenges and find solutions in establishing large virtual health care networks that meet major health care priorities and deliver high volumes of patient consultation/care as their return on investment.  

Medibio CEO, Jack Cosentino said, "We are thrilled to have Dr Darkins join the Medibio board. As a visionary leader in telehealth, he shares our Company's passion for solving one of the world's most significant health epidemics. His experience in building virtual care systems will help us to address the significant, yet under-recognised need for mental health support services globally. His expertise and achievements in the telehealth, IOT and patient care arenas, and leadership experience at organisations, including the UK National Health Service, U.S. Department of Veterans Affairs and Medtronic, complements an incredible team we are developing at Medibio, to exclusively focus on meeting this global need. We look forward to leveraging his knowledge, insights and relationships to heighten Mental Health awareness and identifying ways to reduce the stigma and isolation it can cause."

Medibio Chairman, Chris Indermaur stated,  "We welcome Adam to the board of Medibio and value the addition of his leadership and passion to ours, as we collectively serve people with mental health conditions and seek to meet their aspirations for wellness and recovery."

Further Information: www.medibio.com.au
Medibio Shareholder Enquiries:
Jack Cosentino
CEO and Managing Director Medibio Limited
jack.cosentino@medibio.com.au
T: +1 952 465 4787
Investor Relations Enquiries:
Peter Taylor 
NWR Communications
peter@nwrcommunications.com.au 
T: +61 (0)412 036 231

About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a digital health company that has developed an objective test to assist in the diagnosis of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilises patented (and patent pending) circadian heart rate variability and cloud based proprietary algorithms to deliver a quantifiable measure to assist in clinical diagnosis. Medibio's depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio's application to become the first FDA approved, objective, and evidence-based approach to the diagnosis of mental health disorders. Medibio's technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market. Medibio was founded in Perth, Australia with offices located in Melbourne (VIC), and U.S. offices in Minneapolis, MN and Palo Alto, CA.  Medibio is listed on the Australian Securities Exchange Ltd (ASX) and trades on the OTCQB Venture Market.  Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com and www.asx.com.au




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medibio Limited via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Lantronix to Present at the 11th Annual LD Micro Main Event on December 5, 201819.11.2018 22:15Pressemelding

IRVINE, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Lantronix, Inc. (the “Company”) (NASDAQ: LTRX), a global provider of secure data access and management solutions for the industrial Internet of Things (IoT), today announced that President and CEO Jeff Benck, and CFO Jeremy Whitaker will present an overview of the Company’s business at the 11th Annual LD Micro Main Event on December 5, 2018 at 4 PM Pacific Time (7 PM Eastern Time) at the Luxe Hotel located at 11461 Sunset Boulevard in Los Angeles, California. A live webcast and copy of the Company’s slide presentation will be available on the investor relations section of the Company’s website at www.lantronix.com. Investors attending the conference who wish to meet with Lantronix management should contact Shahram Mehraban at investors@lantronix.com. About Lantronix Lantronix, Inc. is a global provider of secure data access and management solutions for Internet of Things (IoT) assets. Our mission is to be the leading supplier of IoT sol

Lehman Brothers UK Capital Funding V LP: Notice to the Holders of the Preferred Securities19.11.2018 18:03Pressemelding

LONDON, Nov. 19, 2018 (GLOBE NEWSWIRE) -- TEMP: 91SI NOTICE TO THE HOLDERS OF: USD 500,000,000 FIXED RATE ENHANCED CAPITAL ADVANTAGED PREFERRED SECURITIES ("LP V ECAPS") ISSUER: LEHMAN BROTHERS UK CAPITAL FUNDING V LP ("LP V") ISIN: XS0301813522 LIQUIDATION OF LB GP NO.1 LTD ("the Company") AND IMPLICATIONS FOR HOLDERS OF LP V ECAPS THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE REGISTERED AND BENEFICIAL OWNERS OF THE SUBJECT SECURITIES. IF APPLICABLE, ALL DEPOSITORIES, CUSTODIANS AND OTHER INTERMEDIARIES RECEIVING THIS NOTICE ARE REQUESTED TO EXPEDITE THE RE-TRANSMITTAL TO BENEFICIAL OWNERS OF THE SECURITIES IN A TIMELY MANNER. Your attention is drawn to the formal notice contained in the PDF link below concerning the Company, LP V and the LP V ECAPS. In order to view the formal notice, it is recommended that you copy and paste the link into your browser. http://www.rns-pdf.londonstockexchange.com/rns/8119H_1-2018-11-19.pdf If you have any difficulties in openin

Lehman Brothers UK Capital Funding LP: Notice to the Holders of the Preferred Securities19.11.2018 17:53Pressemelding

LONDON, Nov. 19, 2018 (GLOBE NEWSWIRE) -- NOTICE TO THE HOLDERS OF: EUR 225,000,000 FIXED RATE TO CMS-LINKED GUARANTEED NON-VOTING, NON-CUMULATIVE PERPETUAL PREFERRED SECURITIES ("LP I Securities") ISSUER: LEHMAN BROTHERS UK CAPITAL FUNDING LP ("LP I") ISIN: XS0215349357 LIQUIDATION OF LB GP NO.1 LTD ("the Company") AND IMPLICATIONS FOR HOLDERS OF LP I SECURITIES THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE REGISTERED AND BENEFICIAL OWNERS OF THE SUBJECT SECURITIES. IF APPLICABLE, ALL DEPOSITORIES, CUSTODIANS AND OTHER INTERMEDIARIES RECEIVING THIS NOTICE ARE REQUESTED TO EXPEDITE THE RE-TRANSMITTAL TO BENEFICIAL OWNERS OF THE SECURITIES IN A TIMELY MANNER. Your attention is drawn to the formal notice contained in the PDF link below concerning the Company, LP I and the LP I Securities. In order to view the formal notice, it is recommended that you copy and paste the link into your browser. http://www.rns-pdf.londonstockexchange.com/rns/8123H_1-2018-11-19.pdf If

Lehman Brothers UK Capital Funding IV LP: Notice to the Holders of the Preferred Securities19.11.2018 17:46Pressemelding

LONDON, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Amsterdam Stock Exchange: 49AC NOTICE TO THE HOLDERS OF: EUR 200,000,000 EURO FIXED RATE ENHANCED CAPITAL ADVANTAGED PREFERRED SECURITIES ("LP IV ECAPS") ISSUER: LEHMAN BROTHERS UK CAPITAL FUNDING IV LP ("LP IV") ISIN: XS0282978666 LIQUIDATION OF LB GP NO.1 LTD ("the Company") AND IMPLICATIONS FOR HOLDERS OF LP IV ECAPS THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE REGISTERED AND BENEFICIAL OWNERS OF THE SUBJECT SECURITIES. IF APPLICABLE, ALL DEPOSITORIES, CUSTODIANS AND OTHER INTERMEDIARIES RECEIVING THIS NOTICE ARE REQUESTED TO EXPEDITE THE RE-TRANSMITTAL TO BENEFICIAL OWNERS OF THE SECURITIES IN A TIMELY MANNER. Your attention is drawn to the formal notice contained in the PDF link below concerning the Company, LP IV and the LP IV ECAPS. In order to view the formal notice, it is recommended that you copy and paste the link into your browser. http://www.rns-pdf.londonstockexchange.com/rns/8115H_1-2018-11-19.pdf If you

Algeco Announces Third Quarter 2018 Financial Results Conference Call19.11.2018 16:04Pressemelding

LONDON, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Algeco Investments B.V. (together with its subsidiaries, “Algeco”), the leading global business services provider of modular space, secure portable storage solutions and remote workforce accommodations, today announced that it will hold its third quarter 2018 financial results conference call on Monday 26 November 2018 at 3:00pm GMT (10:00 a.m., Eastern Time). To access the call, please dial: UK: +44 3333000804 or 08003589473 (UK toll free) US: +1 6319131422 or +1 855 85 70686 (US toll free) and enter participant PIN code 84969282# approximately ten minutes prior to the start of the call. You will be placed on hold until the event begins. The conference call will also be broadcast over the internet with an accompanying slide presentation. To join the web conference, go to https://event.on24.com/wcc/r/1884864/AA4F091A2F921FE451DDBD688F19B26F. Please enter your name, email address and company to join the call. The customer service team can be rea

Bombardier to supply 19 OMNEO Premium trains for the Hauts-de-France region’s intercity lines19.11.2018 15:31Pressemelding

OMNEO Premium will provide about 25% more seating capacity to intercity travelers between Paris and the Hauts-de-France region A comfortable double-deck train offering new features such as newly-designed spacious seats, easier platform access and ample baggage space BERLIN, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Note to editors: To view the photo associated with this press release, please visit the following link: http://www.globenewswire.com/NewsRoom/AttachmentNg/683009f7-6c0e-4ab2-8800-5bb87399c7e0 Mobility technology leader Bombardier Transportation announced today that it received an order for 19 BOMBARDIER OMNEO Premium double-deck trains from the French National Railway Corporation, Société nationale des chemins de fer français (SNCF) on behalf of the Hauts-de-France region. This call-off order is part of the contract signed in 2010 with SNCF to provide up to 860 double deck-trains to French regions and is valued at approximately 256 million euro ($291 million US), including price esc

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom